Maquet nets EU, U.S. approval for intra-aortic balloon pump

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Maquet Cardiovascular has received FDA 510(k) clearance and CE mark for its new Cardiosave intra-aortic balloon pump (IABP).

The new Cardiosave IABP incorporates a touchscreen display. The pump is being offered in two configurations: Cardiosave Hybrid for routine in-hospital use and Cardiosave Rescue for use in ambulances and aircraft.

Intra-aortic balloon counterpulsation is an adjunctive therapy that is often used in patients with left ventricular failure and other cardiac conditions. When the IABP is inserted into the patient's aorta, it counterpulsates with the heart and augments coronary blood flow to increase myocardial oxygen supply and decrease myocardial oxygen demand.

Cardiosave is expected to be commercially available in the U.S. in January 2012.